In short: #1, +348.8% — "the best-performing partner pick of the year." A clinical-stage biotech in targeted breast-cancer therapy: "Olema Pharmaceuticals grabbed attention because it could be the next big cancer drug success. The company's lead breast cancer therapy called palazestrant… showed promising early trial data." No revenue, no valuation and no view — the archetype of the risk the introduction warns about.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.